AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
Limiting tariffs on medtech products remains a priority for advocacy organization AdvaMed, president Scott Whitaker said during a Jan. 21 media briefing. The call was held to introduce new AdvaMed chairman of the board Mick Farrell, ResMed’s CEO and a member of the AdvaMed board since 2015.
Whitaker acknowledged that the Trump administration’s tariff policy “has not necessarily landed where we had originally hoped it would.” But...
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
Vitestro's automated blood drawing robot received CE marking on August 28. The company is limiting release of the robot over the next 12 months to a small number of selected hospitals, with plans to scale up production thereafter.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
